Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Quality of Life of Non-transplant Candidate Multiple Myeloma Patients Treated With Early Bortezomib

This study has been completed.
Information provided by (Responsible Party):
Janssen Korea, Ltd., Korea Identifier:
First received: January 29, 2010
Last updated: July 16, 2013
Last verified: July 2013
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: July 2011
  Primary Completion Date: July 2011 (Final data collection date for primary outcome measure)